KaNDy Therapeutics

A clinical-stage company focused on optimizing the potential of
NT-814 as a non-hormonal breakthrough treatment for multiple symptoms of the
menopause.

[KaNDy Therapeutics @KandyBiotech]

Encouraging news out from the @BBC today, as #menopause is added to the school curriculum for the first time. Watch the below video for more information. https://t.co/xv3i3Bd2K4

[KaNDy Therapeutics @KandyBiotech]

Bayer to acquire UK-based biotech KaNDy Therapeutics Ltd
https://t.co/3nVEritx4D

[KaNDy Therapeutics @KandyBiotech]

30% of women with symptoms of #menopause have found their symptoms worsen during #COVID19 https://t.co/e8SBsRt3qO Read our abstract published in @TheEndoSociety to learn more about our #nonhormonal approach to tackle distressing symptoms of the menopause https://t.co/0Ma5oPnvpX

[KaNDy Therapeutics @KandyBiotech]

VCs are finally ready to talk about menopause | PitchBook https://t.co/4E2rw1IEsH via @PitchBookNews

[KaNDy Therapeutics @KandyBiotech]

Our ENDO 2020 abstract showing that NT-814 has potential to
treat endometriosis and uterine fibroids through modulation of oestrogen is now
published in the Journal of the Endocrine Society. #endometriosis #uterinefibroids Read more: https://t.co/cO8seP5aeL

[Menopause Journal @MenopauseJrnl]

Editor’s Pick: Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal #women: a placebo-controlled, randomized clinical trial https://t.co/ybYfHs3I4Z @MenopauseOrg @Lippincott #menopause

[KaNDy Therapeutics @KandyBiotech]

You can now read our accepted ENDO 2020 SWITCH-1 abstract
discussing the unique findings from a Phase 2b study with NT-814. Significant
improvement in hot flash frequency, sleep, mood and quality of life were seen. #menopause #nonhormonal https://t.co/V2yYdaVask

[DelveInsight @delve_insight]

According to the #DelveInsight estimate, #Vasomotor Symptoms #Market Size is expected to grow at a #CAGR of 7%. Some of the Major Players in the #VasomotorSymptoms Market include #FerventPharma, @AstellasEurope, @KandyBiotech, #MithraPharma and others.
https://t.co/ba2SrgjhCi

[Rachel Braun Scherl @RBScherl]

Mary Kerr CEO of @KandyBiotech & #NeRReTherapeutics has not let doubt deter her in her quest to bring a #treatment for symptoms of #menopause to the market https://t.co/iWtZ99Qtug #menopausematters #womenshealth #womenleaders #orgasmicleadership #femalefounders #investinwomen

[KaNDy Therapeutics @KandyBiotech]

Today we also want to raise awareness about the debilitating symptoms of the #menopause as women of menopause age are the fastest growing portion of the UK workforce. We are aiming to tackle this problem with our #nonhormonal drug candidate, NT-814 https://t.co/7JkN8m8hIY #IWD

[KaNDy Therapeutics @KandyBiotech]

Today we celebrate International Women’s Day and shine a spotlight on women’s achievements. This year’s theme focuses on the difference individuals can make to collectively help create a gender equal world, a statement we certainly support #EachforEqual #IWD2020

[KaNDy Therapeutics @KandyBiotech]

Interesting article in the @DailyMailUK discussing how 1 in 4 women suffering from the #menopause feel ignored by doctors. More awareness about the condition is needed to provide patients the help they need https://t.co/x8krapxCt5

[Channel 5 News @5_News]

The menopause affects all women, but a lack of understanding means that many aren't getting the help they need.

A new survey has revealed that even some medical professionals don't have the necessary knowledge of the subject.

@MumsnetTowers | @50Sense | @Dianedanz

[KaNDy Therapeutics @KandyBiotech]

"Menopause is one of the strongest, most impactful, and most discriminatory taboos still existing in the workplace."

[KaNDy Therapeutics @KandyBiotech]

There are 61 million women over the age of 50 in the U.S. workforce - the fastest growing portion of the U.K. workforce

[KaNDy Therapeutics @KandyBiotech]

There are 61 million women over the age of 50 in the U.S. workforce - the fastest growing portion of the U.K. workforce

[Dr Louise Newson @drlouisenewson]

This great article from the @HarvardBiz delves into the topic of #menopause in the workplace and why, even though there are more women over the age of 50 in employment than ever before, there is still a taboo surrounding the topic: https://t.co/OaYLbiDEgz

[KaNDy Therapeutics @KandyBiotech]

Many women at the peak of their careers consider leaving their job because of menopause symptoms.

[50Sense (LizzieCarrEllis) @50Sense]

Menopause can hit anyone, that's why we need more awareness and education. Thank you @LaurenChiren Dorothy Byrne & @Dianedanz

#KnowYourMenopause

https://t.co/PZTYxtx3En

[KaNDy Therapeutics @KandyBiotech]

We are very pleased to announce that data from our RELENT-1 study with non-hormonal drug candidate, NT-814, has been published in the Menopause
Journal.
Read more here: https://t.co/ov82JzVX51

[Richard A Anderson @profdicanderson]

Big step forward for midlife women’s health treatment options - non- hormonal and highly effective treatment for hot flushes day and night read https://t.co/MC6ZywWtVl

[KaNDy Therapeutics @KandyBiotech]

Great to have our Co-founder and CEO, Dr Mary Kerr, featured in this months’ @ConsiliumHC newsletter. You can read the full interview here https://t.co/cP4cJOdq7N

[KaNDy Therapeutics @KandyBiotech]

Exciting to see @KandyBiotech listed as one of the seven European #FemTech companies aiming to reclaim the discussion and champion #womenshealth You can read the full article below. #nonhormonal #menopause

[150sec @150sec]

#Femtech market is set to be worth $50 billion by 2025. These #europeanstartups are normalising women's bodies and championing data-informed decisions around #WomensHealth health.
https://t.co/W3ohf922pA